stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
49.25
4.46
+9.96%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Net income
Enliven Therapeutics, Inc.'s net income for fiscal 2025 was −$103.7M, compared with −$89.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$105.9M. Over the past ten years it has ranged from −$103.7M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Enliven Therapeutics, Inc. ranks 433rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$103.7M | — |
| FY2024 | −$89.0M | — |
| FY2023 | −$71.6M | — |
| FY2022 | −$37.7M | — |
| FY2021 | −$51.4M | — |
| FY2020 | −$41.4M | — |
| FY2019 | −$23.5M | — |
| FY2018 | −$11.3M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$32.5M | — |
| Mar 2026 | −$23.6M | — |
| Dec 2025 | −$29.7M | — |
| Sep 2025 | −$20.1M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$103.7M
High $0.00
Ten-year median
−$41.4M
Current reading's percentile
11
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item